e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Antibiotic efficacy varies based on the infection model and treatment regimen for
Pseudomonas aeruginosa
Cristina Cigana, Serena Ranucci, Alice Rossi, Ida De Fino, Medede Melessike, Alessandra Bragonzi
Source:
Eur Respir J, 55 (3) 1802456; 10.1183/13993003.02456-2018
Journal Issue:
March
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Cristina Cigana, Serena Ranucci, Alice Rossi, Ida De Fino, Medede Melessike, Alessandra Bragonzi. Antibiotic efficacy varies based on the infection model and treatment regimen for
Pseudomonas aeruginosa
. Eur Respir J, 55 (3) 1802456; 10.1183/13993003.02456-2018
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis
Source: Eur Respir J , 49 (4) 1600851; DOI: 10.1183/13993003.00851-2016
Year: 2017
Effects of direct lung dosing of Tobramycin in a rat chronic infection model using Pseudomonas aeruginosa RP73
Source: International Congress 2018 – Mechanisms of respiratory infection
Year: 2018
Novel Pseudomonas aeruginosa scoring system to guide empiric anti-pseudomonal therapy in COPD patients with community-acquired pneumònia
Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections
Year: 2020
PcrV antibody prophylaxis in combination with antibiotic therapy reduces lung injury and improves survival in pseudomonas aeruginosa infected mice
Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections
Year: 2011
Comparison between two protocols of preventing treatment of chronic
Pseudomonas aeruginosa
(
Pa
) infection
Source: Eur Respir J 2005; 26: Suppl. 49, 620s
Year: 2005
Exploring the susceptibility of P. aeruginosa biofilms in human mucus towards tobramycin treatment
Source: International Congress 2017 – Cystic fibrosis: clinical issues
Year: 2017
Inhaled phage therapy for the treatment of acute Pseudomonas aeruginosa lung infections
Source: International Congress 2018 – Mechanisms of respiratory infection
Year: 2018
An experience of moxifloxacin (MOX) use in therapy of nosocomial pneumonia (NP) in patients who hadn‘t risk factors to be infected by
Pseudomonas aeruginosa
Source: Eur Respir J 2005; 26: Suppl. 49, 187s
Year: 2005
The impact of testosterone on Pseudomonas aeruginosa pathogenicity and antimicrobial susceptibility
Source: International Congress 2018 – Mechanisms of respiratory infection
Year: 2018
Long-term, low-dose azithromycin treatment reduces the prevalence of
staphylococcus aureus
, but selects for macrolide resistance in Danish CF-patients
Source: Annual Congress 2007 - Cystic fibrosis: the balance between treatment and side-effects
Year: 2007
Predicting the outcome of respiratory Pseudomonas aeruginosa infection in vivo
Source: International Congress 2017 – Cystic fibrosis: treatments and monitoring
Year: 2017
Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis},
Source: Eur Respir J 2012; 40: 1014-1023
Year: 2012
Pseudomonas aeruginosa
in patients with cystic fibrosis - a comparison of early eradication and conventional therapy
Source: Eur Respir J 2004; 24: Suppl. 48, 385s
Year: 2004
In vitro activity of colistin in combination with N-acetylcysteine against Pseudomonas aeruginosa
Source: International Congress 2018 – Cystic fibrosis in paediatric patients: current research
Year: 2018
Effects of erythromycin on Pseudomonas aeruginosa adherence to collagen and morphology in vitro
Source: Eur Respir J 2003; 21: 401-406
Year: 2003
Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and
Pseudomonas aeruginosa
infection
Source: Eur Respir J 2005; 26: Suppl. 49, 620s
Year: 2005
Immunomodulatory properties of macrolide antibiotics in the treatment of bronchial sepsis involving
P. aeruginosa
Source: Eur Respir J 2004; 24: Suppl. 48, 639s
Year: 2004
Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia
Source: Eur Respir J 2009; 33: 394-400
Year: 2009
Persistence and genetic adaptation of Pseudomonas aeruginosa in patients with COPD.
Source: Virtual Congress 2020 – Airway infection: the microbiome and beyond
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept